M4344+Niraparib for Ovarian Cancer (PARP Trial)

"At this time, recruitment for this medical trial has ceased. It was initially published on December 1st 2022 and last modified on January 21 of the same year. However, if you're in search of other studies that might fit your needs, there are presently 1498 trials seeking patients with recurrent ovarian cancer and 99 investigations recruiting participants to assess M4344+Niraparib as a treatment option."

"Currently, there are 99 scientific investigations in progress that focus on M4344+Niraparib. These trials span the globe with 2817 different sites participating; 13 of these studies have entered Phase 3. Although Washington, District of Columbia is home to many such clinical studies, other locations around the world take part as well."

"At present, there are 99 operational clinical trials involving M4344+Niraparib spanning 49 nations and 485 cities. The original trial for this drug combination was conducted in 2016 by Myriad Genetics, Inc.. This Phase 3 study included 733 patients and has since been supplemented with 17 additional medical studies."

"According to clinicaltrials.gov, this research is not presently enrolling participants. The trial was first announced on December 1st 2022 and most recently revised on January 21st of the same year. Despite its current inactivity, there are still 1597 other studies actively seeking volunteers for their trials."

"The safety of M4344+Niraparib is estimated at 1 due to its Phase 1 status, revealing a lack of clinical data confirming efficacy and safety."